Money
Filter News
Found 67,206 articles
-
There’s plenty of money on the move as venture capital firms and investors look to the future of biotech. Read on for today’s top Series A rounds.
-
BioSpace Publishes 2021 U.S. Life Sciences Salary Report, Examines Salary Growth Despite Challenges
6/23/2021
As BioSpace releases its third annual 2021 U.S. Life Sciences Salary Report, there are hopeful surprises and unsettling truths. -
The Third Rock Ventures-backed startup has a pipeline of Treg therapeutics aimed at multiple sclerosis, type 1 diabetes and inclusion body myositis.
-
Money on the Move: June 16 – 22
6/23/2021
Life sciences advances continue to be an exciting opportunity for investors. Here's a glance at the companies attracting fresh funding the past week. -
Qu Biologics Receives Additional Funding to Accelerate Clinical Development of Qu’s First-in-Class Immunotherapeutic for COVID-19 Prevention and Treatment
6/23/2021
Qu Biologics Inc. is pleased to announce it is receiving advisory services and additional research and development funding of up to $1,971,195 funding from the National Research Council of Canada Industrial Research Assistance Program.
-
Tvardi Therapeutics Raises $74 Million in Series B Financing to Advance Clinical Programs
6/23/2021
Tvardi Therapeutics, Inc. has closed a $74 million Series B financing.
-
Strand Therapeutics Raises $52M in Oversubscribed Series A Round
6/23/2021
Strand Therapeutics today announced that the company raised $52 million in an oversubscribed Series A financing round.
-
RapidPulse Launches With $15 Million Series A Financing for Ischemic Stroke TherapyIndustry Veterans Join Team to Support the Development of Novel Cyclic Aspiration System for Ischemic Stroke
6/23/2021
RapidPulse, Inc. today announced the closing of a $15 million Series A financing.
-
xCures raises $12.69 million in Series A funding for their AI-powered precision oncology platform
6/23/2021
xCures Inc., the leader in the patient-centric use of artificial intelligence (AI) and predictive modeling, announced today that it has raised $12.69 million in Series A funding
-
Phoenix PharmaLabs Successfully Completes Second Oversubscribed Netcapital Offering Raising more than $1 million to Fund Continued Development of Company’s Two Non-Addictive Opioid Compounds for Acute and Chronic Pain
6/23/2021
Phoenix PharmaLabs, Inc. today announced it has completed a second successful round of financing raising $1.07 million via the Netcapital ( https://netcapital.com ) equity funding portal.
-
Adela Debuts with $60M in Series A Financing and a Breakthrough Approach to Blood-Based Detection of Cancer and Other Diseases
6/23/2021
Adela (formerly DNAMx) has launched with $60 million USD in Series A financing to enable the detection of cancer and other high-morbidity, high-mortality conditions through a blood test that harnesses the potential of the methylome
-
Orum Therapeutics Closes $84 Million Series B Financing to Advance Novel Targeted Protein Degrader Payloads into Clinical Trials for Cancer
6/23/2021
Orum today announced the close of a $84 million Series B financing.
-
Glycomine Closes $68 Million Series B to Advance into Clinical Trials a Novel Treatment for PMM2-CDG, a Rare Glycosylation Disease
6/23/2021
Glycomine, Inc. today announced that it has closed a $68 million Series B financing.
-
Jaguar Health Set to Join Russell Microcap Index
6/23/2021
Jaguar Health, Inc. announced that Jaguar is set to join the Russell Microcap® Index at the conclusion of the 2021 Russell indexes annual reconstitution, effective after the US market opens on June 28, 2021, according to a preliminary list of additions posted by FTSE Russell.
-
Quanta Raises $245 Million to Accelerate Commercialization of its SC+ Portable Hemodialysis System
6/23/2021
Quanta Dialysis Technologies Ltd, a medical technology leader delivering on its vision for more flexible and accessible dialysis care, announced that it has raised $245 million in an oversubscribed and upsized Series D round, the largest private funding round for a dialysis device company in history.
-
Vita Therapeutics Raises $32 Million in Oversubscribed Series A Financing Led by Cambrian Biopharma to Advance the Development of Therapies to Treat Muscular Dystrophies
6/23/2021
Vita Therapeutics today announced the completion of an oversubscribed $32 million Series A.
-
BiondVax Announces First Quarter 2021 Financial Results and Provides Business Update
6/23/2021
BiondVax Pharmaceuticals Ltd., a biopharmaceutical company focused on developing, manufacturing and ultimately commercializing products for the prevention and treatment of infectious diseases and related illnesses, published its first quarter financial results for the quarter ended March 31, 2021.
-
ImmuneID Announces Close of $50 Million Series A Financing to Develop Precision Immunology Therapeutics
6/23/2021
ImmuneID, Inc. today announced that it has raised $50 million in Series A financing.
-
Sierra Oncology Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - June 23, 2021
6/23/2021
Sierra Oncology, Inc., a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer, granted a stock option to a new employee as approved by the Compensation Committee of the Company's Board of Directors, under Sierra Oncology's 2018 Equity Inducement Plan.
-
BioSpace Publishes 2021 Salary Report, Highlighting Salary Growth Despite Challenges
6/23/2021
BioSpace, the leader in biopharma news and careers has published it’s 2021 U.S. Life Sciences Salary Report.